Skip to main content

Day: December 4, 2023

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1...

Continue reading

Chijet Announces Financial Results for the Six Months Ended June 30, 2023

YANTAI, China, Dec. 04, 2023 (GLOBE NEWSWIRE) — Chijet Motor Company, Inc. (Nasdaq: CJET) (“Chijet” or “we”, “our”, or the “Company”), a high-tech enterprise engaged in the development, manufacture, sales, and service of traditional fuel vehicles and new energy vehicles (“NEV”) in China, today announced its unaudited financial results for the six months ended June 30, 2023. Financial Summary for the Six Months Ended June 30, 2023 (all results compared to the six months ended June 30, 2022, unless otherwise noted)Revenues were $2.6 million, a decrease of 73.2% Units of vehicles sold reached 309, a decrease of 71.8% Parts and Other sales reached $0.5 million, a decrease of 78.4% Gross margin was negative 670%, compared with negative 215% Net loss was $57.6 million, compared with $48.3 millionRecent Development We have consummated...

Continue reading

Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) —  NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1...

Continue reading

JOANN Announces Third Quarter Fiscal 2024 Results And Increases Top-Line Full Year Outlook

Net sales totaled $539.8 million; eCommerce sales up 11.5% to last year Gross profit of $282.1 million increased 0.4% compared to the third quarter of last year 52.3% gross margin, a 240-basis point year-over-year improvement Line of sight to now deliver $225 million in targeted annual cost reductions under Focus, Simplify and Grow initiativeHUDSON, Ohio, Dec. 04, 2023 (GLOBE NEWSWIRE) — JOANN Inc. (NASDAQ: JOAN) (“JOANN”), the nation’s category leader in fabric and sewing with one of the largest assortments of arts and crafts products, today reported results for its third quarter of fiscal year 2024 which ended October 28, 2023. Chris DiTullio, JOANN’s Chief Customer Officer and co-lead of the Interim Office of the CEO commented, “With continued progress and strong execution against our strategic priorities, we were pleased...

Continue reading

GitLab Reports Third Quarter Fiscal Year 2024 Financial Results

Quarterly revenue of $149.7 million, up 32% year-over-year Fiscal Third Quarter Highlights:Total revenue of $149.7 million GAAP operating margin of (27)%; Non-GAAP operating margin of 3% GAAP net loss per share of $(1.84); Non-GAAP net income per share of $0.09SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) — All-Remote – GitLab Inc. (NASDAQ: GTLB), The DevSecOps Platform, today reported financial results for its third quarter fiscal year 2024, ended October 31, 2023. “We delivered a strong quarter, which was driven by the continued adoption of our DevSecOps Platform,” said Sid Sijbrandij, GitLab CEO and co-founder. “GitLab is the only DevSecOps company that integrates security, compliance, and AI into one platform. With enterprises facing complexity from all directions, they need a partner to help them realize business...

Continue reading

CanAsia Energy Announces $4 Million Brokered Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Dec. 04, 2023 (GLOBE NEWSWIRE) — CanAsia Energy Corp. (“CanAsia” or the “Company”) (CEC – TSXV) announced today a brokered private placement offering (“Offering”) of up to 40,000,000 CanAsia common shares at an issue price of CAD $0.10 per share to raise aggregate gross proceeds of up to CAD $4.0 million. The Offering is being led by Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”) on a “best-efforts” basis. CanAsia officers and directors have advised CanAsia of their intention to participate in the Offering by purchasing Accredited Investor Shares for aggregate gross proceeds of up to $1.8 million. CanAsia intends to use the net proceeds from the offering, combined with CanAsia’s previously...

Continue reading

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Dr. Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery. Dr. Boneva’s career began at a specialized Mathematics school where she excelled in Engineering. However, it wasn’t until she went on health mission trips that she discovered her true passion for helping patients. She decided to pursue a career in medicine and trained...

Continue reading

POET Technologies Announces Closing of US$1.6 Million Underwritten Public Offering of Common Shares and Warrants

TORONTO, Dec. 04, 2023 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today announced the closing of its previously announced underwritten public offering in the United States (the “Offering”). The Offering consisted of 1,600,000 common shares of the Company and warrants to purchase up to 1,600,000 common shares of the Company at a combined public offering price of US$0.90 (CAD$1.22) per common share and accompanying warrant. Each warrant has an exercise price of US$1.12 (CAD$1.52) per common share and is exercisable for five years from the date of issuance. In addition, the Company...

Continue reading

Avance Gas Holding Ltd: Addition to the Board of Directors

Bermuda, December 4, 2023 Avance Gas Holding Ltd (“Avance Gas” or the “Company”) announces that Will Homan-Russell has today been elected as a new board member in the Company. Will Homan-Russell is an experienced professional investor in the maritime sector, currently serving as Chief Investment Officer of UK based WMC Capital Ltd., where he co-founded Albemarle Shipping Fund. From 2003 to 2018 he worked for Tufton Oceanic Limited, a fund management company specializing in investments in the maritime and energy sectors. Mr. Homan-Russell has served as a board member of SFL Corporation Ltd. since July 2022. He holds a MA in Mathematics from Oxford University and an MSc. in Finance from London Business School. For further queries, please contact: Media contact: Øystein Kalleklev, CEO Tel: +47 23 11 40 00 Investor and Analyst contact: Randi...

Continue reading

Grieg Seafood ASA: Trade subject to notification – shares for employees 2023

On 27 June 2023, Grieg Seafood ASA’s annual general meeting authorized Grieg Seafood ASA (the “Company“) to sell Grieg Seafood ASA shares owned by it to Grieg Seafood group employees in connection with the Company’s share saving program (the “Program“). The purpose of the Program is to strengthen Grieg Seafood’s culture and to encourage loyalty through employees becoming shareholders of the Company. Grieg Seafood ASA has today started the transfer of 107 473 Grieg Seafood ASA shares held by it to employees participating in the Program (the “Participants“). The shares have been purchased at a subscription price of NOK 65,8935 per share (the “Subscription Price“) before discount. The Subscription Price corresponds to the volume-weighted average share price as traded on Oslo...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.